BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 20590442)

  • 1. The sequence-dependent cytotoxic effect of trastuzumab in combination with 5-Fluorouracil or cisplatin on gastric cancer cell lines.
    Li XL; Yi SQ; Xu JM; Zhang Y; Yingying-Feng ; Chen W; Song ST
    Cancer Invest; 2010 Dec; 28(10):1038-47. PubMed ID: 20590442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells.
    Ding X; Qu X; Fan Y; Che X; Qu J; Xu L; Liu J; Liu Y
    Anticancer Drugs; 2014 Mar; 25(3):315-22. PubMed ID: 24300914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines.
    Gong SJ; Jin CJ; Rha SY; Chung HC
    Cancer Lett; 2004 Oct; 214(2):215-24. PubMed ID: 15363548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification.
    Tomioka H; Mukohara T; Kataoka Y; Ekyalongo RC; Funakoshi Y; Imai Y; Kiyota N; Fujiwara Y; Minami H
    Int J Oncol; 2012 Aug; 41(2):551-8. PubMed ID: 22614071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin.
    Kim SY; Kim HP; Kim YJ; Oh DY; Im SA; Lee D; Jong HS; Kim TY; Bang YJ
    Int J Oncol; 2008 Jan; 32(1):89-95. PubMed ID: 18097546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells.
    Torii Y; Kato R; Minami Y; Hasegawa K; Fujii T; Udagawa Y
    Anticancer Res; 2014 Jan; 34(1):107-15. PubMed ID: 24403450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.
    Menendez JA; Mehmi I; Lupu R
    J Clin Oncol; 2006 Aug; 24(23):3735-46. PubMed ID: 16847284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer.
    Saeki H; Yanoma S; Takemiya S; Sugimasa Y; Akaike M; Yukawa N; Rino Y; Imada T
    Oncol Rep; 2007 Aug; 18(2):433-9. PubMed ID: 17611667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer.
    Satoh T; Omuro Y; Sasaki Y; Hamamoto Y; Boku N; Tamura T; Ohtsu A
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):949-55. PubMed ID: 22116464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.
    Fujimoto-Ouchi K; Sekiguchi F; Yasuno H; Moriya Y; Mori K; Tanaka Y
    Cancer Chemother Pharmacol; 2007 May; 59(6):795-805. PubMed ID: 17031648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
    Klos KS; Zhou X; Lee S; Zhang L; Yang W; Nagata Y; Yu D
    Cancer; 2003 Oct; 98(7):1377-85. PubMed ID: 14508823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted HER2 treatment in advanced gastric cancer.
    Jørgensen JT
    Oncology; 2010; 78(1):26-33. PubMed ID: 20185938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab.
    Eto K; Iwatsuki M; Watanabe M; Ida S; Ishimoto T; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
    Ann Surg Oncol; 2014 Jan; 21(1):343-50. PubMed ID: 24154840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma.
    Kim R; Tanabe K; Inoue H; Toge T
    Int J Oncol; 2002 Mar; 20(3):549-55. PubMed ID: 11836567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro.
    Budman DR; Tai J; Calabro A
    Breast Cancer Res Treat; 2007 Jul; 104(1):93-101. PubMed ID: 17004104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.
    Chen W; Wei F; Xu J; Wang Y; Chen L; Wang J; Guan X
    Int J Mol Med; 2011 Dec; 28(6):985-91. PubMed ID: 21887460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab has opposing effects on SN-38-induced double-strand breaks and cytotoxicity in HER2-positive gastric cancer cells depending on administration sequence.
    Yamade M; Sugimoto M; Nishino M; Uotani T; Sahara S; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Miyajima H; Furuta T
    Anticancer Res; 2012 Jan; 32(1):105-14. PubMed ID: 22213294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy.
    Wen XF; Yang G; Mao W; Thornton A; Liu J; Bast RC; Le XF
    Oncogene; 2006 Nov; 25(52):6986-96. PubMed ID: 16715132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.